CN113024450A - Dithio-methyl cobalt (III) complex and preparation method and application thereof - Google Patents
Dithio-methyl cobalt (III) complex and preparation method and application thereof Download PDFInfo
- Publication number
- CN113024450A CN113024450A CN202110370955.6A CN202110370955A CN113024450A CN 113024450 A CN113024450 A CN 113024450A CN 202110370955 A CN202110370955 A CN 202110370955A CN 113024450 A CN113024450 A CN 113024450A
- Authority
- CN
- China
- Prior art keywords
- iii
- complex
- cobalt
- ester
- dithiomethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 238000010668 complexation reaction Methods 0.000 title description 2
- JAWGVVJVYSANRY-UHFFFAOYSA-N cobalt(3+) Chemical compound [Co+3] JAWGVVJVYSANRY-UHFFFAOYSA-N 0.000 claims abstract description 49
- 150000002148 esters Chemical class 0.000 claims abstract description 28
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 18
- 201000011510 cancer Diseases 0.000 claims abstract description 7
- 238000000338 in vitro Methods 0.000 claims abstract description 7
- NPIHYGZWEUGMNG-QINSGFPZSA-N (Z)-[phenyl(pyridin-2-yl)methylidene]hydrazine Chemical compound C=1C=CC=NC=1C(=N/N)\C1=CC=CC=C1 NPIHYGZWEUGMNG-QINSGFPZSA-N 0.000 claims abstract description 6
- 238000011503 in vivo imaging Methods 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims abstract description 5
- 238000001429 visible spectrum Methods 0.000 claims abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 239000003446 ligand Substances 0.000 claims description 18
- 229910052751 metal Inorganic materials 0.000 claims description 11
- 239000002184 metal Substances 0.000 claims description 11
- 239000013078 crystal Substances 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 7
- 229910001429 cobalt ion Inorganic materials 0.000 claims description 4
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 claims description 4
- BZJIPQBBHNRUOC-UHFFFAOYSA-K cobalt(3+) N,N-dimethylcarbamodithioate Chemical compound CN(C([S-])=S)C.[Co+3].CN(C([S-])=S)C.CN(C([S-])=S)C BZJIPQBBHNRUOC-UHFFFAOYSA-K 0.000 claims description 4
- NPIHYGZWEUGMNG-NTCAYCPXSA-N (e)-[phenyl(pyridin-2-yl)methylidene]hydrazine Chemical compound C=1C=CC=NC=1C(=N/N)/C1=CC=CC=C1 NPIHYGZWEUGMNG-NTCAYCPXSA-N 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 238000000799 fluorescence microscopy Methods 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 1
- 238000003384 imaging method Methods 0.000 abstract description 12
- 230000001093 anti-cancer Effects 0.000 abstract description 7
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract description 3
- 229960004316 cisplatin Drugs 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 8
- 201000002528 pancreatic cancer Diseases 0.000 description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 229910017052 cobalt Inorganic materials 0.000 description 4
- 239000010941 cobalt Substances 0.000 description 4
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002946 anti-pancreatic effect Effects 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000012990 dithiocarbamate Substances 0.000 description 3
- -1 dithiocarbamate schiff base Chemical class 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010201 enrichment analysis Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000004879 molecular function Effects 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- GCSHUYKULREZSJ-UHFFFAOYSA-N phenyl(pyridin-2-yl)methanone Chemical compound C=1C=CC=NC=1C(=O)C1=CC=CC=C1 GCSHUYKULREZSJ-UHFFFAOYSA-N 0.000 description 2
- 238000000575 proteomic method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000035924 thermogenesis Effects 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- NPIHYGZWEUGMNG-UHFFFAOYSA-N [phenyl(pyridin-2-yl)methylidene]hydrazine Chemical compound C=1C=CC=NC=1C(=NN)C1=CC=CC=C1 NPIHYGZWEUGMNG-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000398 anti-amebic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 238000012984 biological imaging Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 1
- 230000006860 carbon metabolism Effects 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000023500 cellular component organization or biogenesis Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000004700 cobalt complex Chemical class 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 150000004699 copper complex Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000006571 energy metabolism pathway Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000006846 excision repair Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007269 microbial metabolism Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 238000003068 pathway analysis Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a dithiomethyl ester cobalt (III) complex and a preparation method and application thereof, wherein the cobalt (III) complex has a chemical formula of [ Co [ [ III ]III(L)2]·NO3Wherein HL is: (Z) -2- (phenyl (pyridin-2-yl) methylene) hydrazine carbothiomethyl ester. The cobalt (III) complex is simple to prepare, has obvious fluorescence in the visible spectrum region of 450-650 nm, and can be used for in vitro cell imaging and in vivo imaging. The complex has micromolar anticancer activity which is obviously superior to that of cisplatin. Further proteomics studies revealed that the ability of the complexes to perform their anti-cancer capacity is likely to be through inhibition of tumor cellsQuantitative metabolism. The complex of the invention can be used for imaging and treating cancer, and has good application value.
Description
Technical Field
The invention relates to a cobalt complex, in particular to a dithiomethyl cobalt (Co) (III) complex and a preparation method and application thereof.
Background
For decades, transition metal complexes have been the focus of attention in medicinal chemistry due to their broad coordination geometry, number and type of coordinating metal ions, variable redox states, and choice of coordinating ligands. Cobalt is an essential trace element found in all animals and is used as a cofactor for vitamin B12. Thus, it can regulate DNA synthesis and maintain normal functions of the nervous system and brain. There is also evidence that vitamin B12 is essential for fatty acid and amino acid metabolism and proper red blood cell formation. The coordination chemistry of cobalt is mainly determined by co (ii) and co (iii) derivatives. Having a low spin d6The cobalt (III) complex with electronic configuration can be reduced to d7Cobalt (II) complexes, thus facilitating the leaving of the ligand. Thus, co (iii)/co (ii) is commonly used to design and develop redox-activated metal prodrugs. Recently, many cobalt (III) complexes have found potential application in medicine. For example, the cobalt (III) complex of diacetone ethylene diimine (Doxovir) has recently completed phase II clinical trials as an effective biocide.
On the other hand, dithiocarbamate schiff base ligands, whose general structure is similar to tridentate heterocyclic thiocarbamamines and ligands, have recently received much attention for their antiproliferative, anti-amoebic and antibacterial activities. Moreover, these ligands have both soft sulfur and hard nitrogen donor atoms, which can coordinate with various metal ions to form metal complexes with interesting physicochemical properties and enhanced biological properties. Therefore, in the field of medicinal inorganic chemistry, Co complexes with dithiocarbamate schiff base ligands show broad prospects as anticancer agents.
Cellular imaging of metal-based complexes can provide useful information about their potential biological applications. In the case of cancer treatment, compound imaging not only provides information about the exact tumor location, size, shape and relationship to surrounding tissue, but also allows real-time monitoring of therapeutic agents and their release or activation in the tumor, thereby allowing better treatment planning and prediction of treatment response. The application discloses a dithiomethyl ester Co (III) complex which not only has good anti-cancer capability in vitro and in vivo, but also can be used for living cells or biological imaging outside vitro.
Disclosure of Invention
The present invention provides a compound capable of chelating cobalt ionsZ) A ligand of (E) -2- (phenyl (pyridine-2-yl) methylene) hydrazine carbodithiomethyl ester, and a dithiomethyl ester cobalt (III) complex is synthesized by utilizing the ligand.
The technical scheme for realizing the purpose of the invention is as follows:
a dithio-methyl cobalt (III) complex with a chemical formula of [ CoIII(L)2]·NO3Wherein HL is: (Z) -2- (phenyl (pyridin-2-yl) methylene) hydrazine carbodithiomethyl ester; the Co (II) metal coordinates with the ligand, the hydrogen on HL is removed, the ligand becomes anion, so the chemical formula is expressed by L; at the same time, co (ii) is rapidly oxidized in solution to co (iii) complexes due to air oxidation.
The structural formula of the dithiomethyl ester cobalt (III) complex is as follows:
x-ray single crystal diffraction shows that the dithio-methyl ester cobalt (III) complex belongs to a triclinic system and a space groupP-1; the unit cell parameters are:a (Å) 9.6521(3), b (Å) 10.1324(3), c (Å) 16.8711(6), α (o) 80.874(6), β(o) 80.754(6), γ (o) 88.934 (6); the central metal + 3-valent cobalt ion in the complex and two mercaptan type modes of HL form a hexa-coordination structure.
The preparation method of the cobalt (III) complex shown in the formula is as follows:
mixing Co (NO)3)2·6H2O is added to a mixture containingZ) -2- (phenyl (pyridin-2-yl) methylene) hydrazine carbodithiomethyl ester in methanol, stirring at room temperature for 10 min; then standing at room temperature, crystallizing, and collecting crystals to obtain the dithiomethyl cobalt (III) complex;
the Co (NO)3)2·6H2O and (Z) -2- (phenyl (pyridin-2-yl) methylene) hydrazine carbodithiomethyl ester in a molar ratio of 1: 2;
the above (A) toZ) The ratio of (E) -2- (phenyl (pyridin-2-yl) methylene) hydrazine carbothiomethyl ester to methanol solution was 1 mmol:10 mL.
During preparation, the raw materials can be added according to the multiple of the mixture ratio.
The invention also aims to provide the application of the cobalt (III) dithiomethylester complex in cancer cell imaging, and researches show that the complex can be enriched in mitochondria of pancreatic cancer cells (BxPC-3).
It is another object of the present invention to provide the use of said cobalt (III) dithiomethylester complexes for in vivo imaging.
The invention also aims to provide the application of the cobalt (III) dithiomethylester complex in preparing anti-cancer (such as pancreatic cell carcinoma) medicaments.
The invention has the advantages that:
(1) through simple experimental steps and experimental conditions, the method has high efficiencyZ) -2- (phenyl (pyridin-2-yl) methylene) hydrazine carbodithiomethyl ester ligands and their cobalt (III) complexes.
(2) The cobalt (III) complexes of the invention can be used for both in vitro and in vivo imaging.
(3) The cobalt (III) complex can effectively kill cancer cells and shows good anti-cancer capability in vivo.
Drawings
FIG. 1 is a schematic diagram of the crystal structure of a cobalt (III) dithiomethylester complex of the present invention. For simplicity, solvent water molecules are deleted.
FIG. 2 is a co-localization image of human pancreatic cell carcinoma cells co-incubated with the cobalt (III) dithiomethylester complex of the present invention and the mitochondrial dye MitoTracker Deep FM.
FIG. 3 is a photograph of an image of a nude mouse injected with cobalt (III) dithiomethylester complex.
FIG. 4 is a graph showing the effect of different doses of cobalt (III) dithiomethylester complex on the growth volume of transplanted tumors in nude mice of human pancreatic cell carcinoma (CFPAC-1).
FIG. 5 is a graph of the body weight effect of different doses of cobalt (III) dithiomethylester complex on human pancreatic cell carcinoma (CFPAC-1) xenografts.
Figure 6 is differential accumulation proteins of GO functional class.
Figure 7 is GO enrichment analysis differentially expressed proteins.
FIG. 8 is a pathway analysis of differentially expressed proteins based on the KEGG database.
Detailed Description
The technical solution of the present invention will be further described in detail with reference to specific examples.
3- (4, 5-Dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide (MTT), phenyl (pyridin-2-yl) methanone, hydrazine carbothiomethyl ester and Co (NO)3)2·6H2O was purchased from Sigma-Aldrich. All remaining reagents and solvents were obtained from commercial sources and used without further purification.
（1）（Z) -synthesis and characterization of 2- (phenyl (pyridin-2-yl) methylene) hydrazine carbodithiomethyl ester ligand (HL):
by refluxing phenyl (pyridin-2-yl) methanone (0.92 g, 5 mmol) and hydrazine carbothiomethyl ester (0.61 g, 5 mmol) in MeOH for 1 h to give a ligand: (Z) -2- (phenyl (pyridin-2-yl) methylene) hydrazine carbothiomethyl ester as a yellow solution. Slow evaporation of the solvent at 4 ℃ gave a yellow product of HL in 1.19 g (82%). Calculated value C14H13N3S2(287.40) C, 58.51, H, 4.56 and N, 14.62. Found value of C, 58.22; H, 4.71; N, 14.32。m/z: 286.06 [M – H]+。
(2) Synthesis and structural characterization of Dithio methyl ester Co (III) Complex:
adding 5 mmol of Co (NO)3)2·6H2O was added to a solution of 10 mmol of HL ligand in methanol (100 mL) and stirred at room temperature for 10 min. The mixed solution was then left to stand at room temperature, and a brown massive dithiomethyl ester co (iii) complex was obtained by slowly evaporating the filtrate solvent, with a yield of 63%. Calculated value C28H30CoN7O6S4(747.26) C, 45.00, H, 3.97 and N, 13.12. Found C, 45.67, H, 3.56, N, 13.58.
And (3) single crystal structure characterization: data for the dithiomethyl ester co (iii) complex was collected on a Bruker SMART Apex II CCD diffractometer with a Mo-K α source of λ = 0.71073 a at room temperature. The structure of the complex was solved by a direct method and structurally optimized using the SHELXTL 5.1 software package. And (4) refining anisotropic thermal vibration parameters of all non-hydrogen atoms. Selected dithiomethyl Co (III) complexes [ CoIII(L)2]·NO3·3H2The O crystal parameters and bonding parameters are listed in tables 1 and 2.
TABLE 1 Crystal data for the dithiomethyl Co (III) complex;
table 2. bond length (a) and bond angle (q) of the dithiocarbamate mixed-valence copper complex;
x-ray single crystal diffraction shows that the dithio-methyl ester cobalt (III) complex belongs to a triclinic system and a space groupP-1. As shown in figure 1, the central metal + 3-valent cobalt ion in the complex forms a hexa-coordination structure with two thiol modes of HL.
(3) In-vitro anti-pancreatic cancer activity study of dithio-methyl cobalt (III) complex:
human pancreatic cancer cells (CFPAC-1, BxPC-3 and AsPC-1) and human normal embryonic lung fibroblasts (WI-38) were cultured in a complete medium containing 10% fetal bovine serum and 1% streptomycin/penicillin in an incubator containing 5% CO at 37 ℃. As can be seen in Table 3, IC for the Co (III) complexes50IC with values significantly lower than HL ligand50Values indicate that the anticancer activity of HL ligands is significantly affected by cobalt metal coordination. In addition, the Co (III) complex showed better in vitro anti-pancreatic cancer activity than cisplatin, IC for CFPAC-1, BxPC-3 and AsPC-1 cells, Co (III) complex50The values are respectively 8.2-, 4.1-and 3.9-fold lower than those of cisplatin.
TABLE 3 IC inhibition of human pancreatic cancer cell line growth by cobalt (III) dithiomethylester complex50Value (48 h,. mu.M);
(4) dithiomethyl ester cobalt (III) complex cellular imaging studies:
cellular imaging of metal-based complexes can provide useful information about their potential biological applications. Several metal complexes with intrinsic fluorescence, such as ir (iii), re (i) and zn (ii) complexes, can facilitate cell imaging in living cells. As shown in FIG. 2, confocal fluorescence microscopy was able to observe the imaging ability of cobalt (III) dithiomethylester complex in BxPC-3 cells of human pancreatic cancer. Co-localization studies using MitoTracker Deep Red FM showed that the green and Red signals largely combined to form a yellow color, confirming the accumulation of cobalt (III) dithiomethylester complex primarily in the mitochondrial region. Targeting mitochondria has significant advantages. Because mitochondria serve as a source of power for eukaryotic cells, mitochondrial dysfunction can prevent rapid growth of cancer cells and even lead to their death. And the anti-cancer drugs in mitochondria can avoid the nuclear excision repair mechanism, thereby restoring DNA drug addicts. In addition, mitochondria located in tumor cells are more prone to mitochondrial dysfunction than normal cells.
(5) Dithiomethyl ester cobalt (III) complex in vivo imaging studies:
the small animal living body imaging technology adopts a high-sensitivity refrigeration CCD matched with a special imaging dark box and image processing software, so that the distribution condition of the medicine in a living body organism can be directly monitored. Injecting the Co (III) complex into the abdominal cavity of a BALB/c nude mouse at a dose of 4 mg/kg, and obtaining the fluorescence imaging under the same exposure intensity and exposure time after injecting the medicine for 0, 30, 60 and 120 min respectively. Imaging with 455-495 nm excitation and 535 nm emission. Immediately after the injection of the dithiomethyl ester cobalt (III) complex, there was no fluorescence signal in vivo. As shown in fig. 3, after 30 minutes, strong in vivo fluorescence was observed, revealing the potential role of cobalt (III) dithiomethylester complexes in bioimaging, which is not limited to in vitro or living cells. After 2 hours, although the in vivo fluorescence decreased, it was still evident that the half-life of the cobalt (III) dithiomethylester complex was long, and has potential for in vivo imaging.
(6) Anti-pancreatic cancer effect of cobalt (III) dithiomethylester complex in vivo:
firstly, a CFPAC-1 xenograft tumor model of human pancreatic cell carcinoma is established. The operation is as follows: taking CFPAC-1 cells in logarithmic growth phase, inoculating the cells under the right axilla of 30 nude mice under aseptic condition, wherein the inoculation amount of the cells is 5 multiplied by 106One/only. Measuring the diameter of the transplanted tumor by using a vernier caliper until the tumor grows to 100 mm3On the left and right, 30 tumor-bearing nude mice with good growth state and good tumor size uniformity were selected and randomly divided into 3 groups of 10 mice each, i.e., a control group, a cobalt (III) dimethyldithiocarbamate complex high dose group (4 mg/kg), and a cobalt (III) dimethyldithiocarbamate complex low dose group (2 mg/kg). As shown in FIG. 4, after day 15 of administration, tumor volumes were reduced in the 2 mg/kg and 4 mg/kg dose groups relative to the control group (P)<0.05); while the body weights of the mice in the 2 mg/kg and 4 mg/kg dose groups were not significantly different from those of the mice in the control group (FIG. 5). These results indicate that cobalt (III) dithiomethylester complexes have an effect on the treatment of CFPAC-1 tumors of human pancreatic cancer.
(7) Proteomics research of dithiomethyl ester cobalt (III) complex:
proteomic analysis is a high resolution and high throughput process that can provide advanced information on the protein level related to disease or biological processes, and this knowledge is very useful for revealing the potential anti-cancer mechanisms of therapeutic agents. Thus, in order to obtain the mechanism of action of cobalt (III) dithiomethylester complexes, proteomic analysis based on Tandem Mass Tags (TMT) was performed.
To obtain the biological effect of differentially expressed proteins, GO analysis was performed on cobalt (III) dithiomethylester complexes, a technique that employs the Gene Ontology classification system to interpret Gene sets, and assigns genes into a series of predefined classes based on their functional properties. GO analysis provides a general description framework for functional annotation and classification of gene datasets. The method comprises the following three aspects: cellular components, molecular functions and biological processes. As shown in FIG. 6, cellular component analysis showed that most of the differential proteins were of the cell part, organelle part, organelle, membrane and protein-containing complex, based on > 40% gene percentage in GO entry. For molecular functions, the major differential proteins belong to binding and catalytic activity. The major differential proteins in biological processes are stress to stimulus, biological regulation, cellular process, metabolic process and cellular component organization or biogenesis. To determine if differentially expressed proteins were significantly enriched in certain functional classes, we further performed enrichment analysis of the differentially expressed proteins using the GO classification. The 10 most abundant GO items are shown in fig. 7. Further, a significantly enriched KEGG pathway was investigated and signal transduction and metabolic pathways significantly affected by cobalt (III) dithiomethylester complex treatment could be identified. As shown in fig. 8, the 10 most important pathways of action are: microbial metabolism in secondary environments, Metabolic pathways, Carbon metabolism, Biosynthesis of secondary metabolites, Citrate cycles (TCA cycle), Valine, leucine and isoluteine degradation (Valine, leucine and isoleucine degradation), proteosomes (Proteasome), Thermogenesis (Thermogenesis), Oxidative phosphorylation and Epstein-Barr virus infection (EB virus infection). From the above 10 action pathways, we can find that the cobalt (III) dithiomethylester complex acts on cancer cells mainly through energy metabolic pathways.
Claims (6)
1. A dithio-methyl-ester cobalt (III) complex, which is characterized in that the chemical formula of the complex is [ CoIII(L)2]·NO3Wherein HL is: (Z) -2- (phenyl (pyridin-2-yl) methylene) hydrazine carbodithiomethyl ester; the Co (II) metal coordinates with the ligand, the hydrogen on HL is removed, the ligand becomes anion, so the chemical formula is expressed by L;
the structural formula of the complex is as follows:
x-ray single crystal diffraction shows that the dithio-methyl ester cobalt (III) complex belongs to a triclinic system and a space groupP-1; the unit cell parameters are:a (Å) 9.6521(3), b (Å) 10.1324(3), c (Å) 16.8711(6), α (o) 80.874(6), β (o) 80.754(6), γ (o) 88.934 (6); the central metal + 3-valent cobalt ion in the complex and two mercaptan type modes of HL form a hexa-coordination structure.
2. The process for preparing a cobalt (III) dimethyldithiocarbamate complex according to claim 1, wherein: mixing Co (NO)3)2·6H2O is added to a mixture containingZ) -2- (phenyl (pyridin-2-yl) methylene) hydrazine carbodithiomethyl ester in methanol, stirring at room temperature for 10 min; then standing at room temperature, crystallizing, and collecting crystals to obtain the dithiomethyl cobalt (III) complex.
3. The process for preparing a cobalt (III) dimethyldithiocarbamate complex according to claim 2, wherein:
the Co (NO)3)2·6H2O and (Z) -2- (phenyl (pyridin-2-yl) methylene) hydrazine carbodithiomethyl ester in a molar ratio of 1: 2;
the above (A) toZ) The ratio of (E) -2- (phenyl (pyridin-2-yl) methylene) hydrazine carbothiomethyl ester to methanol solution was 1 mmol:10 mL.
4. Use of a cobalt (III) dithiomethyl ester complex according to claim 1, wherein: the dithiomethyl cobalt (III) complex has obvious fluorescence in the green region of a visible spectrum of 450-600 nm, can be used for fluorescence imaging of in vitro cancer cells and preparing a cancer cell fluorescence probe.
5. Use of a cobalt (III) dithiomethyl ester complex according to claim 1, wherein: the dithiomethyl cobalt (III) complex is excited by 455-495 nm wavelength to generate obvious fluorescence in vivo, and can be used for in vivo imaging.
6. Use of a cobalt (III) dithiomethyl ester complex according to claim 1, wherein: application in preparing antitumor drugs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110370955.6A CN113024450B (en) | 2021-04-07 | 2021-04-07 | Dithio-methyl cobalt (III) complex and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110370955.6A CN113024450B (en) | 2021-04-07 | 2021-04-07 | Dithio-methyl cobalt (III) complex and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113024450A true CN113024450A (en) | 2021-06-25 |
| CN113024450B CN113024450B (en) | 2022-07-26 |
Family
ID=76453901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110370955.6A Active CN113024450B (en) | 2021-04-07 | 2021-04-07 | Dithio-methyl cobalt (III) complex and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113024450B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101260121A (en) * | 2007-03-07 | 2008-09-10 | 卡南吉医药科技（上海）有限公司 | Complex compound of heteroaromatic thiosemicarbazone and transition metal, and application thereof in preparing antineoplastic medicine |
| WO2010138820A2 (en) * | 2009-05-28 | 2010-12-02 | President And Fellows Of Harvard College | N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation |
| CN111548360A (en) * | 2020-05-13 | 2020-08-18 | 桂林医学院附属医院 | Dithiocarbamic acid mixed-valence copper complex and preparation and application thereof |
-
2021
- 2021-04-07 CN CN202110370955.6A patent/CN113024450B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101260121A (en) * | 2007-03-07 | 2008-09-10 | 卡南吉医药科技（上海）有限公司 | Complex compound of heteroaromatic thiosemicarbazone and transition metal, and application thereof in preparing antineoplastic medicine |
| WO2010138820A2 (en) * | 2009-05-28 | 2010-12-02 | President And Fellows Of Harvard College | N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation |
| CN111548360A (en) * | 2020-05-13 | 2020-08-18 | 桂林医学院附属医院 | Dithiocarbamic acid mixed-valence copper complex and preparation and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| C. L. CHEN，等: "Antitumor Activity of Manganese(II) and Cobalt(III) Complexes of 2 Acetylpyridine Schiff Bases Derived from S Methyldithiocarbazate: Synthesis, Characterization,and Crystal Structure of the Manganese(II) Complex of 2 Acetylpyridine S Methyldithiocarbazate", 《RUSSIAN JOURNAL OF COORDINATION CHEMISTRY》 * |
| MING XUE LI，等: "Mn(II), Co(II) and Zn(II) complexes with heterocyclic substituted thiosemicarbazones: Synthesis, characterization, X-ray crystal structures and antitumor comparison", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113024450B (en) | 2022-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2944627B1 (en) | Nanometersized metal salen complex compounds, their preparation and their use as systemic antitumor agents | |
| Begum et al. | Synthesis, characterization, biological and catalytic applications of transition metal complexes derived from Schiff base | |
| Ouyang et al. | Potent anticancer activity of a new bismuth (III) complex against human lung cancer cells | |
| JP2017519004A (en) | Texaphyrin-platinum (IV) conjugates and compositions for use in overcoming platinum resistance | |
| CN111377975A (en) | Novel mitochondrion-targeted iridium complex and preparation method and application thereof | |
| CN111205311A (en) | Novel high-antitumor-activity white leaf vine zinc (II) complex and synthesis method and application thereof | |
| CN102627685B (en) | Nitric oxide-donating glutathione compound, preparation method and medical purpose thereof | |
| CN113024450B (en) | Dithio-methyl cobalt (III) complex and preparation method and application thereof | |
| CN103833623A (en) | Amino acid-amine conjugate and preparation method and application thereof | |
| CN111728981A (en) | Quercetin rare earth complex and preparation method thereof | |
| CN111138372A (en) | Preparation and application of acetylpyrazine thiosemicarbazone metal chelating agent and metal complex thereof | |
| CN107501303B (en) | Copper (II) complex and its synthetic method and application that a kind of brufen and quinoline-8-formaldehyde schiff bases are constructed | |
| JP2004502696A (en) | Ruthenium (II) compounds for cancer treatment | |
| CN102875462B (en) | Anti-tumor 2-amino nicotinonitrile, application and preparation method thereof | |
| CN110256482B (en) | Heteropoly vanadate compound and preparation method thereof | |
| CN109705158B (en) | Independent double-center Ag complex and preparation method and anticancer activity evaluation thereof | |
| Cheng et al. | Folic acid mediated cisplatin magnetic nanodrug targeting in the treatment of oral squamous cell carcinoma | |
| CN110016048B (en) | Derivative of mitochondrion targeting IR780 iodide, preparation method and application | |
| CN104557990A (en) | Synthesis of zinc phenanthroline aminopolycarboxylate complex and application of complex in anti-tumor drugs | |
| CN106588961A (en) | Binuclear phenanthroline zinc complex and synthetic method and application thereof | |
| CN110423242A (en) | 6,7- dichloroquinoline -5,8- derovatives transient metal complex and its synthetic method and application | |
| CN103288858B (en) | 2-phenylpyridine ketoxime copper compound and preparation method and application | |
| CN106883271A (en) | ONS tridentate ligands Pt (II) complex of antitumor activity and its preparation method and application | |
| CN115160347B (en) | Glycosyl white vine zinc (II) complex and application | |
| US20230373962A1 (en) | Supramolecular molecules for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230904 Address after: Room 504, No. 42, Guangzhou Road, Development Zone, Nantong City, Jiangsu Province, 226000 Patentee after: Jiangsu Simefei Medical Technology Co.,Ltd. Address before: 541002 No.15 Lequn Road, Xiufeng District, Guilin City, Guangxi Zhuang Autonomous Region Patentee before: AFFILIATED HOSPITAL OF GUILIN MEDICAL University |